What is Emend ?

Fosaprepitant Dimeglumine is a prodrug of aprepitant and functions as a neurokinin-1 (NK1) receptor antagonist, used primarily in combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy. Upon administration, it undergoes rapid conversion to aprepitant, which works by blocking the action of substance P, a neuropeptide associated with vomiting reflex. Its efficacy in enhancing patient comfort makes it a valuable component in cancer supportive care regimens.

• fatigue
• diarrhea
• headache
• constipation
• hiccups
• loss of appetite
• dizziness
• heartburn
• indigestion
• stomach pain
• rash

• Hypersensitivity reactions including anaphylaxis have been reported.
• Use with caution in patients with severe hepatic impairment.
• May interact with other medications, including warfarin, leading to alterations in INR levels.
• Pregnancy Category B: Should be used during pregnancy only if clearly needed.
• Not established for pediatric patients under 6 months of age.
• Documented drug interactions with CYP3A4 substrate drugs.
• Patient counseling should include potential of drug interactions and signs of allergic reactions.